Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

Initiating empagliflozin vs a DPP-4 inhibitor may slow the progression of diabetic retinopathy in patients with type 2 ...

Heart attacks are a leading cause of death and disability in Europe, and their effects often extend beyond the initial event, leading to chronic heart failure.

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

The following is a summary of “Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Diabetic retinopathy (DR) affects about 26 percent of people with diabetes. While many patients have an early form of DR, the condition can progress, posing the threat of irreversible vision loss.